Business Description
![West Pharmaceutical Services Inc West Pharmaceutical Services Inc logo](https://static.gurufocus.com/logos/0C000009N9.png?14)
West Pharmaceutical Services Inc
NAICS : 339112
SIC : 3841
ISIN : US9553061055
Share Class Description:
WST: Ordinary SharesDescription
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.44 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 0.41 | |||||
Interest Coverage | 84.46 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 17.63 | |||||
Beneish M-Score | -2.85 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.4 | |||||
3-Year EBITDA Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | 11.9 | |||||
3-Year Book Growth Rate | 16.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 4.45 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.38 | |||||
9-Day RSI | 54.02 | |||||
14-Day RSI | 49.94 | |||||
6-1 Month Momentum % | -13.95 | |||||
12-1 Month Momentum % | -19.56 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.34 | |||||
Quick Ratio | 1.68 | |||||
Cash Ratio | 0.7 | |||||
Days Inventory | 85.42 | |||||
Days Sales Outstanding | 65.18 | |||||
Days Payable | 44.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.26 | |||||
Dividend Payout Ratio | 0.11 | |||||
3-Year Dividend Growth Rate | 5.8 | |||||
Forward Dividend Yield % | 0.26 | |||||
5-Year Yield-on-Cost % | 0.36 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 3.3 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 35.69 | |||||
Operating Margin % | 21.14 | |||||
Net Margin % | 18.25 | |||||
FCF Margin % | 12.41 | |||||
ROE % | 19.08 | |||||
ROA % | 14.31 | |||||
ROIC % | 19.43 | |||||
ROC (Joel Greenblatt) % | 29.91 | |||||
ROCE % | 20.15 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 43.07 | |||||
Forward PE Ratio | 46.5 | |||||
PE Ratio without NRI | 42.83 | |||||
Shiller PE Ratio | 58.69 | |||||
Price-to-Owner-Earnings | 47.28 | |||||
PEG Ratio | 1.95 | |||||
PS Ratio | 7.84 | |||||
PB Ratio | 8.53 | |||||
Price-to-Tangible-Book | 8.95 | |||||
Price-to-Free-Cash-Flow | 63.34 | |||||
Price-to-Operating-Cash-Flow | 30.02 | |||||
EV-to-EBIT | 35.29 | |||||
EV-to-Forward-EBIT | 35.88 | |||||
EV-to-EBITDA | 28.55 | |||||
EV-to-Forward-EBITDA | 28.78 | |||||
EV-to-Revenue | 7.59 | |||||
EV-to-Forward-Revenue | 7.56 | |||||
EV-to-FCF | 61.13 | |||||
Price-to-Projected-FCF | 3.29 | |||||
Price-to-DCF (Earnings Based) | 1.24 | |||||
Price-to-DCF (FCF Based) | 1.84 | |||||
Price-to-Median-PS-Value | 1.35 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.3 | |||||
Price-to-Graham-Number | 4.13 | |||||
Price-to-Net-Current-Asset-Value | 38.52 | |||||
Earnings Yield (Greenblatt) % | 2.83 | |||||
FCF Yield % | 1.63 | |||||
Forward Rate of Return (Yacktman) % | 20.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:WST
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
West Pharmaceutical Services Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 2,876.9 | ||
EPS (TTM) ($) | 7.03 | ||
Beta | 1.14 | ||
Volatility % | 30.39 | ||
14-Day RSI | 49.94 | ||
14-Day ATR ($) | 8.624383 | ||
20-Day SMA ($) | 297.835 | ||
12-1 Month Momentum % | -19.56 | ||
52-Week Range ($) | 265 - 415.73 | ||
Shares Outstanding (Mil) | 72.54 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
West Pharmaceutical Services Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
West Pharmaceutical Services Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
West Pharmaceutical Services Inc Frequently Asked Questions
What is West Pharmaceutical Services Inc(WST)'s stock price today?
The current price of WST is $302.78. The 52 week high of WST is $415.73 and 52 week low is $265.00.
When is next earnings date of West Pharmaceutical Services Inc(WST)?
The next earnings date of West Pharmaceutical Services Inc(WST) is 2024-10-25 Est..
Does West Pharmaceutical Services Inc(WST) pay dividends? If so, how much?
The Dividend Yield %  of West Pharmaceutical Services Inc(WST) is 0.26% (As of Today), Highest Dividend Payout Ratio of West Pharmaceutical Services Inc(WST) was 0.26. The lowest was 0.08. And the median was 0.2. The  Forward Dividend Yield % of West Pharmaceutical Services Inc(WST) is 0.26%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |